152 related articles for article (PubMed ID: 25620327)
1. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.
Rochau U; Jahn B; Qerimi V; Burger EA; Kurzthaler C; Kluibenschaedl M; Willenbacher E; Gastl G; Willenbacher W; Siebert U
Crit Rev Oncol Hematol; 2015 May; 94(2):164-78. PubMed ID: 25620327
[TBL] [Abstract][Full Text] [Related]
2. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
3. The role of decision analytic modeling in the health economic assessment of spinal intervention.
Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
[TBL] [Abstract][Full Text] [Related]
4. Decision analytic modeling in spinal surgery: a methodologic overview with review of current published literature.
McAnany SJ; Anwar MA; Qureshi SA
Spine J; 2015 Oct; 15(10):2254-70. PubMed ID: 26111597
[TBL] [Abstract][Full Text] [Related]
5. Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview.
Rochau U; Qerimi Rushaj V; Schaffner M; Schönhensch M; Stojkov I; Jahn B; Hubalewska-Dydejczyk A; Erlund I; Thuesen BH; Zimmermann M; Moreno-Reyes R; Lazarus JH; Völzke H; Siebert U
Thyroid; 2020 May; 30(5):746-758. PubMed ID: 31964247
[No Abstract] [Full Text] [Related]
6. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
Williams C; Lewsey JD; Mackay DF; Briggs AH
Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
[TBL] [Abstract][Full Text] [Related]
7. Systematic assessment of decision models in Parkinson's disease.
Siebert U; Bornschein B; Walbert T; Dodel RC
Value Health; 2004; 7(5):610-26. PubMed ID: 15367256
[TBL] [Abstract][Full Text] [Related]
8. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges.
Earnshaw SR; Wilson M; Mauskopf J; Joshi AV
Value Health; 2009 Jun; 12(4):507-20. PubMed ID: 19900253
[TBL] [Abstract][Full Text] [Related]
9. [Decision analytic modeling and their impact on health care decision making].
Inotai A; Kaló Z; Mészáros A
Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
[TBL] [Abstract][Full Text] [Related]
10. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
11. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
Soto J
Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.
Pandya C; Hashmi S; Khera N; Gertz MA; Dispenzieri A; Hogan W; Siddiqui M; Noyes K; Kumar SK
Clin Transplant; 2014 Oct; 28(10):1084-91. PubMed ID: 25040732
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
[TBL] [Abstract][Full Text] [Related]
14. Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review.
Goehler A; Geisler BP; Manne JM; Jahn B; Conrads-Frank A; Schnell-Inderst P; Gazelle GS; Siebert U
Pharmacoeconomics; 2011 Sep; 29(9):753-69. PubMed ID: 21557632
[TBL] [Abstract][Full Text] [Related]
15. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
16. Using health state utility values in models exploring the cost-effectiveness of health technologies.
Ara R; Wailoo A
Value Health; 2012; 15(6):971-4. PubMed ID: 22999149
[TBL] [Abstract][Full Text] [Related]
17. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.
Kamal KM; Miller LA; Kavookjian J; Madhavan S
Semin Arthritis Rheum; 2006 Aug; 36(1):50-60. PubMed ID: 16887468
[TBL] [Abstract][Full Text] [Related]
18. Development of a decision-analytic model of stroke care in the United States and Europe.
Chambers MG; Koch P; Hutton J
Value Health; 2002; 5(2):82-97. PubMed ID: 11918824
[TBL] [Abstract][Full Text] [Related]
19. Tutorial in medical decision modeling incorporating waiting lines and queues using discrete event simulation.
Jahn B; Theurl E; Siebert U; Pfeiffer KP
Value Health; 2010; 13(4):501-6. PubMed ID: 20345550
[TBL] [Abstract][Full Text] [Related]
20. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
